Evaluate ACTU stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in ACTU? | Glauxie AI

Q: What are the risks of investing in ACTU?

Actuate Therapeutics Inc (ACTU) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Daniel Schmitt. Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a... Employees: 200,000.

Q: How much debt does ACTU have?

Review ACTU total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is ACTU a good long-term investment?

Evaluate ACTU as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in ACTU?

🦉

Actuate Therapeutics Inc (ACTU)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEODaniel Schmitt

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It...

Key Executives

Name	Title
Alan Kozikowski	Scientific Founder and Advisor
Andrew Mazar	Co-Founder & Chief Operating Officer
Daniel Schmitt	Chief Executive Officer, President & Director
Paul J. Lytle	Chief Financial Officer

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

ACTU Profile Financials

Is ACTU stock safe? How much debt does ACTU have? Is ACTU a good long-term investment?